BACKGROUND: The intra-tendinous tear is a new pathology that is defined as a discontinuity of fibres situated entirely within the tendon. Prolotherapy involves injecting an irritant, such as hyperosmolar dextrose, to stimulate a tissue healing response and ultimately reduce pain. METHODS: 43 consecutive patients diagnosed with an intra-tendinous tear were included (27 males: 16 females, mean (SD) age 41 (11.3). Patients were injected with 0.4ml-1.5ml (mean 0.8ml) of 50% dextrose and 0.5% marcaine mixed in a 1:1 ratio. A 4-6 week period of walking boot immobilisation was followed by progressive rehabilitation (6-8 weeks). Outcomes were assessed with a VISA-A questionnaire at baseline, 3 months and a mean 12.6 (7.0) months post-treatment. Ultrasound scans were conducted before treatment and 5.2 (2.3) weeks later to assess sonographic changes. RESULTS: 30 patients (70%) responded with VISA-A scores increasing by 31 (30.5) points after 3 months (f=0.62, p<0.05) and by 40 (29.3) points after 12.60 (7.0) months (f=0.87, p<0.05). After 5.2 (2.3) weeks, echogenicity was significantly reduced (p<0.05) and 27% of tears were no longer detectable. No significant differences were observed in remaining tears with respect to tear size, tendon thickness or neovascularisation. CONCLUSION: Treatment resulted in clinically significant improvements and controlled trials are warranted. LEVEL OF EVIDENCE: IV.
BACKGROUND: The intra-tendinous tear is a new pathology that is defined as a discontinuity of fibres situated entirely within the tendon. Prolotherapy involves injecting an irritant, such as hyperosmolar dextrose, to stimulate a tissue healing response and ultimately reduce pain. METHODS: 43 consecutive patients diagnosed with an intra-tendinous tear were included (27 males: 16 females, mean (SD) age 41 (11.3). Patients were injected with 0.4ml-1.5ml (mean 0.8ml) of 50% dextrose and 0.5% marcaine mixed in a 1:1 ratio. A 4-6 week period of walking boot immobilisation was followed by progressive rehabilitation (6-8 weeks). Outcomes were assessed with a VISA-A questionnaire at baseline, 3 months and a mean 12.6 (7.0) months post-treatment. Ultrasound scans were conducted before treatment and 5.2 (2.3) weeks later to assess sonographic changes. RESULTS: 30 patients (70%) responded with VISA-A scores increasing by 31 (30.5) points after 3 months (f=0.62, p<0.05) and by 40 (29.3) points after 12.60 (7.0) months (f=0.87, p<0.05). After 5.2 (2.3) weeks, echogenicity was significantly reduced (p<0.05) and 27% of tears were no longer detectable. No significant differences were observed in remaining tears with respect to tear size, tendon thickness or neovascularisation. CONCLUSION: Treatment resulted in clinically significant improvements and controlled trials are warranted. LEVEL OF EVIDENCE: IV.
Authors: Arun Aneja; Spero G Karas; Paul S Weinhold; Hessam M Afshari; Laurence E Dahners Journal: Am J Sports Med Date: 2005-08-10 Impact factor: 6.202
Authors: J M Robinson; J L Cook; C Purdam; P J Visentini; J Ross; N Maffulli; J E Taunton; K M Khan Journal: Br J Sports Med Date: 2001-10 Impact factor: 13.800
Authors: Nicola Maffulli; Vittorino Testa; Giovanni Capasso; Francesco Oliva; Alessio Sullo; Francesco Benazzo; Renato Regine; John B King Journal: Clin J Sport Med Date: 2006-03 Impact factor: 3.638
Authors: Otto Chan; Sarah Morton; Mel Pritchard; Tina Parkes; Peter Malliaras; Tom Crisp; Nat Padhiar; Nicola Maffulli; John King; Dylan Morrissey Journal: Muscles Ligaments Tendons J Date: 2017-05-10